Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2020-04-23

Original market date: See footnote 1

2020-04-23

Product name:

FENTANYL INJECTION BP

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02496186

Product Monograph/Veterinary Labelling:

Date: 2020-02-06 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

STERIMAX INC
2770 Portland Drive
Oakville
Ontario
Canada L6H 6R4

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Epidural ,  Intramuscular ,  Intravenous

Number of active ingredient(s):

1

Schedule(s):

Narcotic (CDSA I)

 

American Hospital Formulary Service (AHFS): See footnote 3

28:08.08 

Anatomical Therapeutic Chemical (ATC): See footnote 4

N01AH01 FENTANYL

Active ingredient group (AIG) number:See footnote5

0123302002

List of active ingredient(s)
Active ingredient(s) Strength
FENTANYL (FENTANYL CITRATE) 2500 MCG / 50 ML

Risk Management Plans See footnote 7

A Canadian Specific Opioid targeted Risk Management Plan (CSO-tRMP) for this product was submitted.

Version 4.0.2
Date modified: